The risk of pancreatic cancer is about 1% chance of developing the disease. Hereditary pancreatic cancer is less common. They usually occur when a gene mutation or change is passed on from one generation to the next in a family. In addition, there are a number of risk factors that increase the likelihood of this disease such as: smoking, age, medical history ....

As for these tumors that form in the endocrine pancreas, this tumor is usually uncommon and is benign. However, if the tumor begins in the exocrine pancreas, it will most likely be malignant (cancerous).

Pancreatic cancer is often difficult to detect because the pancreas is located behind the stomach. If pancreatic cancer is not detected early, it cannot be operated on and is dangerous for the patient. Therefore, the 128-slice CT scan method with high technology, fast, thin slices, sharp quality images will help detect pancreatic cancer and a number of other diseases for timely treatment.

Cancer pain is increasing due to increasing cancer rates, and at the same time cancer is detected and treated early with a longer survival prognosis. The incidence of pain in cancer depends on the type of cancer. A recent study, with an average pain rate of about 73% of primary and secondary cancer patients, of which the highest was 93% of pancreatic cancer patients, 92% of bone and muscle cancer patients had pain.

Pancreatic cancer is a type of cancer that forms in certain cells of the pancreas. Most patients with pancreatic cancer (about 95%) start in the exocrine pancreas. Tumors can also form in the endocrine pancreas, but these are uncommon and are usually benign (not cancerous).

Pancreatic head tumors in particular and pancreatic tumors in general are divided into two types: malignant tumors and benign tumors. Benign pancreatic head tumors are rare, slow-growing, non-metastatic, and pose many of the same dangers as cancerous malignancies.

Progress in the fight against pancreatic cancer has been hampered by many factors. One of them is the inability to detect the disease early in the vast majority of patients. Includes focus on two warning signs - post-pancreatitis diabetes mellitus and excess fat deposition in the pancreas.

Identification of pancreatic cancer markers is essential for cost-effective and outcome-consistent screening. Post-pancreatitis diabetes and fat deposition in the pancreas should be diagnosed early for this purpose.

Hepatopancreatic cancer has a poor prognosis and high mortality rate. To combat this malignancy, aberrant expression and signaling of the ron receptor protein in the pathogenesis as a drug target for therapeutic intervention should be investigated.

Due to the pathological characteristics and complicated treatment process, it is relatively difficult to provide adequate nutrition for pancreatic cancer patients. Poor nutrition will lead to a decrease in the effectiveness of treatment and at the same time make the patient's health worse.

Because pancreatic cancer in the early stages has almost no clinical symptoms and there is still no effective screening method, most of the time when detected, the disease is already at an advanced stage. Up to 40~50% of confirmed cases have distant metastases, and even if the disease has not metastasized, the 5-year survival prognosis for patients does not exceed 5%.